Bioventus Inc.
4721 Emperor Boulevard, Suite 100
Durham, NC 27703
November 1, 2024
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Bioventus Inc. | |
| Registration Statement on Form S-3 | ||
| Filed October 25, 2024 | ||
| File No. 333-282836 |
To whom it may concern:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Bioventus Inc. (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-282836) be accelerated by the Securities and Exchange Commission to 4:00 p.m. Washington D.C. time on November 4, 2024 or as soon as practicable thereafter.
The Company requests that we be notified of such effectiveness by a telephone call to Jennifer A. Yoon of Latham & Watkins LLP at (617) 880-4540 and that such effectiveness also be confirmed in writing.
| Very truly yours, | ||
| Bioventus Inc. | ||
| By: | /s/ Anthony D’Adamio | |
| Anthony D’Adamio | ||
| Senior Vice President, General Counsel, Secretary | ||
| cc: | Wesley C. Holmes, Latham & Watkins LLP |
Jennifer A. Yoon, Latham & Watkins LLP